10 March 2025 : Clinical Research
NSTEMI Risk Prediction with the Combination of the Biomarkers Epicardial Adipose Tissue and Soluble Suppression of Tumorigenicity 2
Jiayu Yin1ACEFG, Bowen Qiu2BCEF, Tingting Li1CE, Yifei Tao3ADE*, Xiaosong Gu1AGDOI: 10.12659/MSM.947019
Med Sci Monit 2025; 31:e947019
Table 3 Association of patient characteristics with major adverse cardiac events at 1 year: Univariate and Cox multivariate regression analysis.
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age, years | 1.05 (1.012–1.085) | 0.009 | 1.05 (1.010–1.082) | 0.011 |
| Male, n (%) | 1.39 (0.832–2.313) | 0.209 | ||
| Body mass index, kg/m | 1.01 (0.934–1.089) | 0.826 | ||
| Current smoker, n (%) | 1.23 (0.734–2.053) | 0.434 | ||
| Diabetes mellitus, n (%) | 1.60 (0.956–2.672) | 0.074 | ||
| Hypertension, n (%) | 1.15 (0.689–1.912) | 0.597 | ||
| Heart rate, bpm | 1.01 (0.987–1.028) | 0.478 | ||
| Total cholesterol, mg/dL | 1.12 (0.943–1.338) | 0.194 | ||
| Triglycerides, mg/dL | 1.07 (0.877–1.302) | 0.511 | ||
| HDL cholesterol, mg/dL | 0.79 (0.433–1.421) | 0.785 | ||
| LDL cholesterol, mg/dL | 1.07 (0.836–1.356) | 0.612 | ||
| Peak hsCRP, mg/L | 1.10 (0.945–1.290) | 0.213 | ||
| Peak hsTnT, ng/L | 1.29 (1.023–1.632) | 0.032 | ||
| Peak NT-pro BNP, pg/mL | 1.05 (0.853–1.285) | 0.658 | ||
| Killip class ≥2, n (%) | 1.79 (0.998–3.223) | 0.051 | ||
| TIMI ≤1, n (%) | 2.17 (0.934–5.053) | 0.072 | ||
| LV ejection fraction, % | 0.92 (0.878–0.954) | <0.001 | 0.95 (0.903–0.990) | 0.016 |
| High sST2 >53.35 (ng/mL) | 3.77 (2.146–6.625) | <0.001 | 3.35 (1.894–5.914) | <0.001 |
| High EATi >44.80 (mL/m) | 5.21 (2.857–9.489) | <0.001 | 4.60 (2.499–8.481) | <0.001 |
| MACEs – major adverse cardiac events; HDL-C – high-density lipoprotein cholesterol; LDL-C – low-density lipoprotein cholesterol; hs-CRP – high-sensitivity C reactive protein; hs-TnT – high-sensitivity cardiac troponin T; NT-proBNP – N terminal pro B type natriuretic peptide; sST2 – soluble suppression of tumorigenicity 2; LV – left ventricular; EAT – epicardial adipose tissue; HR – hazard ratio; CI – confidence interval. | ||||